The incidence of residual neuromuscular blockade in the recovery room is still alarmingly high. In one study, train of four ratios of <0.9 were found in 3.5 to 83% of postoperative patients 1 . These findings stand in a remarkable contrast to the well known harmful implications of residual neuromuscular blockade on patient postoperative outcome. However, even with the best of intentions, dosage and timing of neuromuscular blocking agents (NMBA) reversal with neostigmine can be extremely difficult, and in the context of fast-turnover surgery, potentially impossible 2 . Sugammadex, a γ-cyclodextrin, has recently been reported as an alternative to neostigmine as it rapidly and reliably reverses the effects of steroidal NMBA 3 . However, the costs (200 mg vial approx. A$180) have so far hindered its progress of becoming a widely used alternative to neostigmine. Sugammadex has been licensed for use in Australia since 2010 and the 833-bed tertiary Royal Perth Hospital (RPH) introduced sugammadex in 2010 with the restriction to emercency scenarios (e.g. 'can't intubate, can't ventilate' situation) or when the administration of neostigmine was (relatively) contraindicated.
In February 2011 access to sugammadex was facilitated by successful price negotiations. The pricing was adapted to volume of use; RPH anaesthetists were aware of lower price but not of negotiated 'usage thresholds' between RPH pharmacy and the manufacturer (MSD, Sydney, NSW). This change enabled anaesthetists to choose between neostigmine and sugammadex for the reversal of amino-steroidal NMBA without economic restrictions or restrictions to specific indications (e.g. emergencies). The aim of this retrospective audit was to investigate the impact Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs 
SUMMARY
Sugammadex is known to rapidly and completely reverse the effects of amino-steroidal neuromuscular blocking agents. However, the high costs of sugammadex have so far prevented its introduction as the standard reversal agent in most healthcare systems. At the Royal Perth Hospital, sugammadex was recently introduced as an unrestricted alternative to neostigmine for the reversal of amino-steroidal neuromuscular blocking agents. The aim of this retrospective observational audit was to investigate the impact of this change on clinical practice and associated healthcare costs.
Data from all patients intubated during a one-month period in April to May 2010 and for a similar period in 2011 were retrospectively collected and the use of neuromuscular blocking agents and reversal agents were identified and the associated costs were calculated. More steroidal neuromuscular blocking agents and sugammadex (+743%), but less glycopyrrolate and neostigmine (-48%) were used in 2011. Using the manufacturer's list price, muscle relaxation and reversal costs increased from about A$42 per case to about A$127 per case. Between the investigated time periods no differences were found for anaesthesia time, operating time or time spent in the post anaesthesia care unit. However, there was a statistically significant decrease in the time between surgery and discharge (median 2.0 vs 2.2 days). While the design of the audit was such that no inferences can be made about the cause of this change, this is an interesting observation worthy of further investigation. of this change on choice of NMBA and reversal agent and to calculate the costs of any changes based on the full price of sugammadex. We also aimed to determine whether there were any major changes in length of stay in the post-anaesthesia care unit (PACU) or in the time between surgery and dicharge.
Impact of the IntroductIon of sugammadex

METHODS
Approval was granted by the Ethics Committee and the Quality and Safety Department of the Royal Perth Hospital (A 11-102; 11.3.2011). The need for patient consent was waived as this was acknowledged as an observational audit. Data from all patients tracheally intubated within RPH main theatres (15 theatres) within a one month period (15 April to 14 May) in 2010 and 2011 were obtained respectively and compared. For both periods, the usage of NMBA (succinylcholine, mivacurium, atracurium, cis-atracurium, vecuronium and rocuronium), reversal agents (neostigmine, glycopyrrolate, atropine and sugammadex) and associated costs as well as descriptors of the case mix for each month (including patient age, gender, American Society of Anesthesiologists physical status, urgency of operation, surgical specialty, times of surgery, anaesthesia and PACU stay, time from surgery to discharge) were documented. For the calculation of costs in this paper, the official list price of sugammadex in Australia (200 mg at A$180) and not the price negotiated between RPH pharmacy and the manufacturer was used (due to a confidentiality agreement and the likely variability in outcome of individual hospital negotiations). Demographic data as well as data defining outcome (e.g. perioperative times, time from surgery to dicharge) were collected electronically using the theatre management system at RPH.
Data were retrieved in Microsoft Excel format and later transferred into SPSS (IBM SPSS Statistics version 19) for further analysis. All data were checked for normal distribution (Kolmogorov-Smirnoff test) and are provided as mean ± standard deviation or median (25th/75th percentile) as appropriate. Differences in categorical variables were compared using chi-square or Fisher's Exact tests. The Mann-Whitney U test was used to compare numerical non-parametric data. No sample size calculation was performed as this was as an observational audit which was not testing a hypothesis. Alpha was set at 5%. 
RESULTS
Data from a total of 902 intubated patients (441 in 2010, 461 in 2011) were analysed. The descriptors of the procedural and patient casemix were not significantly different between the two periods, although the audit was not powered to compare these data (Table 1) . Similarly, no differences were found regarding patients' duration of anaesthesia, duration of surgery, the ratio of surgical to anaesthesia time, or the duration of the stay in the PACU ( Table 2 ).
Anaesthetists used more amino-steroidal NMBA in 2011 when compared to 2010 (Table 3) The associated costs for NMBA during the one month period in 2010 were A$8913, with A$9622 for reversal agents, equalling total costs of about $42 per case and A$0.27 per anaesthesia minute. In 2011, NMBA related costs slightly increased to A$9494, but costs of NMBA reversal significantly increased to A$48907, equalling total costs of A$127 per case or $0.88 per anaesthesia minute.
DISCUSSION
The introduction of unrestricted access to sugammadex as an alternative to neostigmine significantly increased anaesthesia related costs. Although this result was certainly to be expected, available data on sugammadex economics have so far mainly been based on assumptions 4, 5 and hence this investigation is one of the first to report such effects in a 'real life' scenario. It has to be noted that we used the official list price of sugammadex in Australia as the underlying base for our calculations. However, internationally (e.g. Japan and Europe) sugammadex is available at a lower price. Furthermore, as in our specific case, healthcare systems or hospitals may individually negotiate with the manufacturer and the resulting price may be lower than the one we used in our calculations. The introduction of unrestricted access to sugammadex (not restricted to specific indications) outside Australia may therefore have a significantly smaller financial impact than the one described by us.
The high take-up rate of sugammadex by the anaesthetists in our department may have been influenced by initial curiosity (gaining experience with a new drug) and the knowledge of the negotiated price for sugammadex. However, it may also have been influenced by anaesthetists' knowledge of benefits of sugammadex over neostigmine. Given unrestricted access to sugammadex, many anaesthetists shifted from NMBA reversal with neostigmine to using sugammadex. This change of practice also showed some, but not all followon effects predicted by Caldwell and Miller in 2009 5 : in line with their prediction, the use of benzylisoquinoline NMBA dramatically decreased. Interestingly, however, and in contrast to a predicted change of practice, for rapid sequence induction succinylcholine was not largely replaced with rocuronium.
Our audit did not observe changes in the length of a patient's stay in the PACU, suggesting no changes in acute postoperative outcomes. However, our sample size may not have been large enough to detect such differences, and some adverse effects of incomplete reversal (e.g. hypoventilation leading to atelectasis) from potential differences in the incidence of residual neuromuscular blockade (not measured in this audit) may be seen only after recovery room discharge.
We observed a median five hour decrease in time from surgery to discharge in the 2011 cohort. This was statistically significant. It would be interesting to speculate that this reduction was related to the increased use of sugammadex, through its improved muscle relaxant reversal, leading to a reduction in pulmonary complications 1,2 . However, importantly, there was a 12 month gap between the two periods and we cannot exclude an influence of a change in hospital culture or policy towards earlier discharge, or other improvements resulting in a faster patient turnover that could explain our results. Therefore, due to the purely observational character of our audit (lack of randomisation or control group in same time interval) we are unable to comment on the cause for the observed differences. Nevertheless, as a shorter stay in the hospital could potentially fully offset cost increases observed in this audit (e.g. average cost for one additional night in hospital approx. US$420 6 ) further prospective research into the potential impact of sugammadex on economic measures of patient outcome is certainly warranted.
CONFLICTS OF INTEREST
Professor Thomas Ledowski has attended a MSD Medical Advisory Board Meeting on sugammadex in Sydney, May 2011, for which a honorarium was paid into a research account of his employer, the University of Western Australia. He has also accepted a grant from MSD (not related to this study).
